ClinicalTrials.Veeva

Menu

Liver Transplantation for Unresectable Liver Limited Colorectal Metastases

Weill Cornell Medicine (WCM) logo

Weill Cornell Medicine (WCM)

Status

Enrolling

Conditions

Unresectable Liver-limited Colorectal Metastases

Treatments

Procedure: Liver transplant

Study type

Observational

Funder types

Other

Identifiers

NCT04742621
20-04021768

Details and patient eligibility

About

This is a single-arm, single institution pilot registry of liver transplantation in patients with unresectable colorectal liver-only metastases at Weill Cornell Medical College. Patients with liver predominant colorectal liver metastases will be screened based on eligibility criteria in a specified clinical hepatobiliary and colorectal liver metastasis tumor board consisting of the principal and co-investigators, representing medical oncology, transplant surgery, radiology, and pathology. The registry aims to track basic demographic data as well as referral patterns, in addition to specific oncologic data such as tumor burden, extent of disease, extent of disease on explant, recurrence rates, patterns of recurrence and survival rates.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Histologically confirmed adenocarcinoma of the colon or rectum
  2. No evidence of extrahepatic metastases or local recurrence based on PET/CT and colonoscopy
  3. No signs of extrahepatic metastases or local recurrence according to PET/CT 4 weeks prior to consideration of transplant
  4. Age 18-65 years old
  5. Good performance status with ECOG 0-1
  6. Stability or regression of liver metastasis for at least 6 months
  7. Minimum of 1 year between diagnosis of colon cancer and liver transplant and 6 months from primary tumor resection and liver transplant
  8. Minimum of 6 months chemotherapy
  9. CEA < 200 ug/L 3 months prior to transplant
  10. Adequate organ and marrow function with Hb > 10 g/dL, ANC > 1000/uL, platelets > 100,000/uL, bilirubin < 2x ULN, AST/ALT < 5x ULN, Creatinine < 1.25 x ULN, Albumin above LLN

Exclusion criteria

  1. Evidence of extrahepatic disease or local recurrence
  2. Previous resection of lung metastases
  3. MSI-H/dMMR or BRAF mutation
  4. Any other medical or co-morbid condition that would preclude liver transplantation, as determined by the transplant team

Trial contacts and locations

1

Loading...

Central trial contact

Benjamin M Samstein, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems